Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group

Απλή σελίδα τεκμηρίου
dc.contributor.authorPectasides, D.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorSyrigos, K.en
dc.date.accessioned2015-11-24T19:29:44Z
dc.date.available2015-11-24T19:29:44Z
dc.identifier.issn0169-5002-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22993
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectCamptothecin/adverse effects/*analogs & derivatives/therapeutic useen
dc.subjectCarcinoma, Small Cell/*drug therapy/pathologyen
dc.subjectCisplatin/adverse effects/*therapeutic useen
dc.subjectDisease Progressionen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Therapy, Combinationen
dc.subjectEtoposide/adverse effects/*therapeutic useen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLung Neoplasms/*drug therapy/pathologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectSurvival Rateen
dc.titleCombination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Groupen
heal.abstractOBJECTIVE: The purpose of this study was to evaluate the efficacy and toxicity of cisplatin, etoposide and irinotecan as first-line treatment in patients with extensive small-cell lung cancer (E-SCLC). PATIENTS AND METHODS: Chemo-naive adult patients with a performance status (PS) of 0-2 and adequate organ function were eligible. Patients received cisplatin 20mg/m(2) i.v. daily for three consecutive days, etoposide 75mg/m(2) i.v. daily for three consecutive days and irinotecan 120mg/m(2) i.v. on day 2, every 21 days for six to eight cycles. Administration of G-CSF was given in the presence of febrile neutropenia and as a 5-day prophylaxis around the recorded nadir day in patients who developed grades 3-4 neutropenia. RESULTS: Fifty-six patients were assessable. The median age was 62.2 years; 96.4% had PS 0-1, 33.5% had >3 metastatic sites. The overall response rate was 80.4% with 8 (14.3%) patients achieving a complete response. The median time to tumor progression was 7.8 months [95% confidence interval (CI), 7.1-8.6 months] with a median survival of 15.1 months [95% CI, 9.7-20.5 months] and 1-year survival rate of 56.5%. One patient died from toxicity. Grades 3-4 neutropenia occurred in 37.5% of patients, grades 3-4 thrombocytopenia occurred in 10.9% of patients and 11 (19.6%) patients developed febrile neutropenia. Grades 3-4 non-hematological toxicities were primarily nausea-vomiting 3.6%, diarrhea 7.1% and fatigue 3.6%. CONCLUSION: This study strongly suggests that cisplatin, etoposide and irinotecan combination is very effective for the treatment of E-SCLC with good safety profile. The triplet regimen currently seems a promising regimen and has to be further explored in phase III trials.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.lungcan.2007.06.027-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17698241-
heal.identifier.secondaryhttp://ac.els-cdn.com/S016950020700400X/1-s2.0-S016950020700400X-main.pdf?_tid=6fda7be28bdd84412d029e4e6eb44bf7&acdnat=1333703544_dd61f8cad53cb795221b0d9e25bb4862-
heal.journalNameLung Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2007-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ